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Effective vaccines against Salmonella Typhi, a major cause of febrile illness in tropical 
regions, can have a significant effect as a disease control measure. Earlier work has 
shown that immunization with either of two Salmonella Typhi vaccines, licensed Ty21a 
or candidate M01ZH09, did not provide full immunity in a controlled human infection 
model. Here, we describe the human humoral immune responses to these oral vaccines 
and their functional role in protection after challenge with S. Typhi. Serum, obtained from 
healthy volunteers before and after vaccination with Ty21a or M01ZH09 or placebo and 
before and after oral challenge with wild-type S. Typhi, was assessed for bactericidal 
activity. Single-dose vaccination with M01ZH09 induced an increase in serum bacteri-
cidal antibodies (p = 0.001) while three doses of Ty21a did not. No association between 
bactericidal activity and protection against typhoid after challenge was seen in either 
vaccine arm. Bactericidal activity after vaccination correlated significantly with delayed 
disease onset (p = 0.013), lower bacterial burden (p = 0.006), and decreased disease 
severity scores (p = 0.021). Depletion of antibodies directed against lipopolysaccharide 
significantly reduced bactericidal activity (p  =  0.009). We conclude that antibodies 
induced after ingestion of oral live-attenuated typhoid vaccines or after challenge with 
wild-type S. Typhi exhibit bactericidal activity. This bactericidal activity is mediated by 
anti-O:LPS antibodies and significantly reduces clinical symptoms but does not provide 
sterile immunity. This directs future vaccine studies toward other antigens or mechanisms 
of protection against typhoid.
Keywords: typhoid infection, bactericidal activity, human challenge model, Salmonella enterica Typhi, immune 
responses
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inTrODUcTiOn
Typhoid fever is a systemic infection caused by Salmonella enterica 
serovar Typhi (S. Typhi) and results in significant morbidity, with 
an estimated 11.9–26.9 million infections occurring each year 
(1, 2). The use of vaccination as a public health prevention measure 
may alleviate significant disease burden, especially as infection 
arises via human-to-human transmission and there is no known 
environmental reservoir (3). Currently, both subunit and live 
oral vaccines against S. Typhi are licensed and recommended for 
use in high-incidence settings by the WHO (4). The protective 
efficacy of the Vi (virulence) capsular polysaccharide vaccine in 
the first year following vaccination is ~69% (5, 6), whereas the live 
oral Ty21a vaccine offers ~35% protection (5, 7). Neither vaccine 
is licensed for use in young children and, as one-third of the cases 
occur under the age of five (1), the development of new vaccines 
is vital.
To enable the development and evaluation of next-generation 
typhoid vaccines, improved characterization of the nature of pro-
tection afforded by vaccination is required. While some protec-
tion against typhoid is thought to be conferred by cell-mediated 
immunity (8), evidence from serosurveillance and vaccine efficacy 
trials indicates that O lipopolysaccharide (O:LPS) and flagellin 
(H) antigens are immunogenic in a dose-dependent manner, and 
that anti-Vi IgG antibody is protective (6, 9). Further description 
of the functional role of these antibodies during infection has been 
evaluated in murine models of S. Typhimurium infection (10) 
and through in vitro studies after immunization (11, 12). While 
these studies suggest that antibodies against both Vi and O9:LPS 
have direct bactericidal activity in the presence of complement, or 
opsonize ahead of pathogen phagocytosis, extrapolation of such 
data to a human infection with S. Typhi has limitations (13).
Using a controlled human infection model (CHIM) of typhoid 
fever, the protective efficacy of two live oral attenuated typhoid 
vaccines (Ty21a and M01ZH09) was recently assessed relative to 
placebo (14, 15). Ty21a, a licensed vaccine, and M01ZH09, a can-
didate vaccine, are derived from the parent strain Ty2. M01ZH09 
was constructed by defined, independently attenuated deletion 
of the ssaV and aroC genes and expresses Vi at negligible levels 
based on immunogenicity measurements (14, 16). Ty21a con-
tains additional genetic attenuations and does not constitutively 
express Vi (17). Neither a single-dose M01ZH09 immunization 
nor three doses of Ty21a provided full immunity in a model where 
diagnosis of typhoid disease (TD) was defined as confirmed S. 
Typhi bacteremia or by ≥12 h of sustained fever ≥38oC (14, 15). 
Here, we explored the functionality of antibodies induced by oral 
vaccination and the association with protection against typhoid 
in the challenge model.
MaTerials anD MeThODs
ethics and approvals
A randomized, double-blind, placebo-controlled trial was 
performed at the Centre for Clinical Vaccinology and Tropical 
Medicine, Churchill Hospital, Oxford, UK (clinicaltrials.gov 
NCT679172; EudraCT 2011-000381-35) (14). This study was 
carried out in accordance with the recommendations of the Oxford 
University Clinical Trials and Research Governance Department, 
and the protocol approved by NRES South Central––Oxford A 
(11/SC/0302) and conducted in accordance with the declara-
tion of Helsinki (2008) and the International Conference of 
Harmonization of Good Clinical Practice guidelines. An inde-
pendent Data Monitoring and Safety Committee monitored the 
trial. To perform the assays described, human complement was 
collected in a parallel, prospective observational study (clinical-
trials.gov NCT01945307; 13/SC/0375). All subjects gave written 
informed consent in accordance with the Declaration of Helsinki.
study Design, Vaccination, and challenge
The study design and results of the primary study objectives of 
the clinical trial have been reported previously (14). Briefly, 99 
adult participants were randomly assigned in the ratio 1:1:1 to 
three study arms: (1) vaccine (a single oral dose of M01ZH09 vac-
cine containing 1 × 1010 CFU live attenuated S. Typhi M01ZH09 
strain), (2) placebo, and (3) comparator (three doses of Ty21a 
capsules each containing 2 × 109 CFU). Participants were chal-
lenged with 104 CFU of wild-type S. Typhi Quailes strain 4 weeks 
after vaccination (D0) (15). Antibiotic treatment was initiated 
at typhoid diagnosis (TD) or 14  days after challenge in those 
participants who were not diagnosed with typhoid fever (nTD). 
Diagnosis of TD was defined as confirmed S. Typhi bacteremia or 
by ≥12 h of sustained fever ≥38oC (14, 15) and full protection was 
defined as not meeting the criteria for diagnosis (nTD).
serum Bactericidal antibody assay
To prepare a source of human complement, fresh serum from a UK 
healthy adult donor was depleted of S. Typhi-binding antibodies 
that may otherwise influence the performance of complement in 
our assays, as modified from Hart et al. (11, 18). Following three 
rounds of adsorption with 1010 CFU of log phase S. Typhi Quailes 
per 1 mL of serum, significant depletion of anti-Vi and anti-O:LPS 
antibody titers was achieved and demonstrated by ELISA (Table 
S1 in Supplementary Material), without change in complement 
activity, as measured by CH100 and AP100 hemolytic assays (data 
not shown). To prepare aliquots of log-phase S. Typhi Quailes for 
the serum bactericidal antibody (SBA) assay, an overnight cul-
ture, set up from a single colony in Luria Bertani broth (LB), was 
diluted 33-fold in LB supplemented with 10% sucrose. This was 
grown at 37oC shaking to achieve 3.5 × 108–3.5 × 109 CFU/mL 
and frozen in aliquots ahead of use in SBA.
Serum samples were evaluated in the SBA from a subset of 
participants from whom serum was available and representing 
similar numbers across all study arms over multiple time points 
(Placebo n = 18, Ty21a n = 16, M01ZH09 n = 18, TD n = 30, 
nTD n = 22). Time points were at pre-vaccination (D28), at chal-
lenge (D0), and post-challenge days 28 (D28), 60 (D60), and 180 
(D180). Briefly, serum samples were de-complemented by heat-
inactivation and diluted before addition of 200 CFU of log phase 
S. Typhi Quailes in Hanks Buffered Saline Solution (HBSS; Life 
Technologies Ltd., UK) supplemented with 0.5% Bovine Serum 
Albumin (BSA; Sigma-Aldrich, UK). S. Typhi-specific antibody-
depleted human complement serum was added to a final com-
plement concentration of 25% and bacteria incubated for 1  h 
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at 37°C with shaking before plating on tryptic soya agar (TSA) 
plates (Oxoid Ltd., UK). In each experiment, complement serum 
and heat-inactivated complement serum alone were included as 
controls for bacterial survival; test samples without complement 
were included to assess any complement-independent killing; 
and a positive control, from another UK healthy donor, to assess 
inter-plate variability. Only experimental plates in which the 
positive control was within twofold of its defined SBA titer and 
with >60% overlap in CFU counts between the complement only 
and heat-inactivated complement only controls were accepted. 
The SBA titer was defined as the reciprocal lowest dilution of test 
serum to achieve ≤50% bacterial killing relative to complement 
alone. The slide agglutination test using Salmonella Vi anti-sera 
(Oxoid Ltd., UK) confirmed that Vi was expressed in the bacte-
rial working stock. In nTD participants bactericidal activity a 
month after challenge (D28) was not measured, as preliminary 
experiments confirmed complete bactericidal activity consistent 
with residual ciprofloxacin in the samples as expected based on 
its pharmacokinetic profile (D28 coincided with the last day of 
antibiotic treatment for this subset) (19).
antigen sources and Purification
Lipopolysaccharide (O9:LPS) was from Sigma-Aldrich, UK 
(L2387, >99% free of protein) and Vi capsular polysaccharide 
was from Sanofi Pasteur, UK (Typhim Vi®). Flagellin (H) was 
purified from a flagellin-deficient S. Enteritidis strain that 
expresses S. Typhi H:d from a plasmid (University of Maryland, 
USA) (14, 20). Cytolethal distending toxin B (CdtB) and pilus 
control protein L (PilL) coding sequences lacking transmem-
brane domains were PCR-amplified from S. Typhi CT18 strain 
genomic DNA, cloned into plasmid pET28b(+) (Novagen, UK) 
and expressed in Escherichia coli BL21(DE3)pLysS (Promega, WI, 
USA). Recombinant His-tagged CdtB and PilL were purified by 
tagging with nickel-coated agarose beads (Ni-NTA, Invitrogen) 
and elution from gravity flow columns (Qiagen, Germany). 
CdtB was renatured in 50-mM sodium phosphate solution and 
500-mM NaCl. hlyE was PCR-amplified from Ty21a, cloned 
into pET21a vector (Novagen, UK), and expressed in an LPS-
modified E. coli BL21 strain to produce endotoxin free proteins 
(Lucigen, ClearCoil BL21 cells). Recombinant His-tagged hemo-
lysin E (HlyE) was purified using HisTrap nickel-affinity column 
(GE Healthcare) followed by desalting on a HiPrep 26/10 (GE 
Healthcare).
elisa
Immunoglobulin G (IgG), IgA, and IgM isotype responses to 
O9:LPS, H, HlyE, CdtB, and PilL were measured in serum as 
previously described (15, 21), with some modifications regard-
ing antigen source and controls. Nominal ELISA units were 
calculated based on standard curves derived from pooled sera 
collected from the highest responders to O-antigen following 
vaccination with M01ZH09 (Emergent BioSolutions, Reading, 
UK). In addition, Vi-specific IgG were measured at D28, D0, and 
D28 using a commercial ELISA kit (VaccZyme™ Human anti-S. 
Typhi Vi IgG Enzyme Immunoassay Kit, The Binding Site Ltd., 
Birmingham, UK) following the manufacturer’s instructions.
antigen-specific and isotype-specific 
antibody-Depletion of sera
In a subset of samples representing all study arms and both TD 
and nTD groups, antibodies specific to H or O9:LPS, or total IgA 
or IgG antibodies were depleted from the serum to assess the con-
tributions of each of these antibodies to the bactericidal activity 
in sera. Antibodies specific to H or O9:LPS were adsorbed on 
to 96-well Maxisorp plates (Nunc, Copenhagen, Denmark) pre-
coated with 1 µg/mL H or 15 µg/mL O9:LPS antigen in carbon-
ate bicarbonate buffer (Sigma, UK), for eight rounds of 30-min 
incubations. A plate coated with BSA was used to create mock 
depleted controls. Total IgA and IgG antibodies were depleted 
using the Dynabeads Antibody coupling kit (Life Technologies 
Limited, UK). Briefly, each diluted serum sample was incubated 
for 1  h with 2-mg magnetic beads coated with either 10  µg of 
goat polyclonal IgG antibody raised against human IgA or IgG 
(AbD Serotec, UK), or an goat polyclonal IgG (Santa Cruz 
Biotechnology, USA). The depletions resulted in approximately 
56% (H), 87% (O9:LPS), 72% (IgA), and 93% (IgG) median 
reduction in the antibody titer, as measured with ELISA.
elispot
Antibody-secreting cell (ASC) responses to LPS, H, and Vi were 
measured at D28, 7 days after vaccination (D21), before challenge 
(D0), Day 7 after challenge (D7), and 48 h after the typhoid diag-
nosis visit (TD + 48) by ELISpot assay, as described in Ref. (14). 
Spots were photographed using the AID ELISpot optical reader 
(AID ELR03m, Autoimmun Diagnostika GmbH, Germany), 
manually counted by two observers, and expressed as spots per 
106 PBMCs. Zero ASC counts were given a nominal value of 0.1 
and 0.1 added to all other observations.
clinical and Microbiological  
Data collection
Daily clinical review and temperature measurements were car-
ried out for 7 days after vaccination and 28 days after challenge. 
In addition, participants collected symptom data daily (solicited 
for headache, feeling generally unwell, loss of appetite, abdominal 
pain, nausea/vomiting, myalgia, arthralgia, cough, diarrhea and 
constipation, and any unsolicited symptoms) (14). Symptom 
severity scores were calculated by summing maximum severity 
values assigned to each of up to 10 symptoms experienced daily 
during 14 days after challenge and deriving the mean (14).
Blood (10  mL) samples were collected for bacterial culture 
at each visit. Cultures were performed by the local hospital 
accredited pathology laboratories according to national stand-
ard operating procedures (22–24), and as previously described 
(14, 15). Quantitative blood culture samples were collected 
immediately prior to antibiotic treatment by inoculation of 
10-mL blood into an ISOLATOR 10 tube (Alere, UK).
cytokine Quantification
Cytokines were quantified in lithium-heparin plasma using 
a multiplex bead-based ELISA (Milliplex® Human cytokine/
chemokine magnetic bead panel, Merck Millipore, UK), follow-
ing the manufacturer’s protocol with dilution of beads by twofold. 
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Analytes tested were as follows: EGF, Fractalkine (CX3CL1), 
GROα (CXCL1), IFNα2, IFNγ, IL1β, IL1RA, IL2, IL6, IL8 
(CXCL8), IL10, IL12p40, IL15, IL17A, IP10 (CXCL10), sCD40L, 
TGFα, TNFα, and VEGF. All samples were run in duplicate and 
were measured on a Luminex MAGPIX instrument (Luminex, 
Netherlands). Values were calculated from the average of dupli-
cates which were above cytokine sensitivity limits and whose %CV 
was <30%.
statistical analysis
SBA titers, ELISA antibody levels, and ASC counts were log10-
transformed before statistical analysis. Within groups, the 
log10-transformed data were still skewed so non-parametric tests 
were used. All reported p-values are based on two-sided tests, 
with significance assumed at p < 0.05, without multiple testing 
corrections. Clinical, laboratory, and immunological data were 
collated using a clinical-trial database (OpenClinica, version 3.1). 
Data analysis was performed using R version 3.2.1 (25).
resUlTs
Kinetics of Bactericidal antibody  
induction and Decay
Sera collected pre-vaccination in all study participants showed 
bactericidal activity against wild-type S. Typhi, with a 2–log10 
range in titers but without significant differences between vac-
cine arms (Figure 1A; Table S2 in Supplementary Material). One 
month after vaccination, at D0, no increase in bactericidal activity 
was observed in either placebo or Ty21a recipients (Figure 1A). 
In contrast, a significant increase in bactericidal activity was 
measured 28 days after M01ZH09 vaccination (p = 0.001). This 
increase was principally attributable to the subset of M01ZH09 
recipients who subsequently went on to be TD after challenge 
(p = 0.009, Figure 1B).
To identify differences in the immune responses induced by 
attenuated vaccines and wild-type S. Typhi, the effect of exposure 
to the challenge agent on levels of bactericidal antibody activity 
was examined. Sixty days after challenge bactericidal antibody 
activity was significantly higher than on D0 in the placebo and 
Ty21a arms in participants with TD after challenge (p = 0.009 and 
p = 0.035, respectively; Figure 1B). The bactericidal activity at 
D60 in sera from nTD placebo and nTD Ty21a recipients showed 
marked variability in inter-individual responses. In contrast, 
D60 titers in M01ZH09 recipients remained unchanged from D0 
in TD participants and waned in nTD participants (p =  0.036; 
Figure 1C).
Evaluation of bactericidal activity in sera from TD individuals 
over a longer time course confirmed that exposure to the challenge 
strain-induced bactericidal antibodies only in placebo and Ty21a 
recipients (Figure 1B). In both groups, titers peaked at D28 after 
challenge and returned to near pre-vaccination baseline levels by 
D180. M01ZH09-vaccinated TD participants had bactericidal 
titers persistently higher than baseline for at least 60 days after 
challenge, despite the apparent absence of any boosting effect by 
exposure to/infection with wild-type challenge.
The impact of Bactericidal antibody 
activity on challenge Outcome
We hypothesized that the presence of circulating bactericidal 
antibodies on the day of challenge may have a protective effect 
on challenge outcome. However, comparison of the bactericidal 
antibody titers between TD and nTD participants at D0 demon-
strated no significant difference in protection (Figure 1D), even 
when assessed by vaccine allocation (Figure S1A in Supplementary 
Material). The similar titer ranges between TD and nTD groups 
indicated that serum bactericidal activity at D0, resulting either 
from preexisting exposure or vaccine induction, did not protect 
against TD.
The D0 bactericidal antibody titers in TD participants were 
positively correlated, however, with time to typhoid diagnosis after 
challenge, when vaccination arms were combined (Figure 2A). 
Furthermore, D0 bactericidal antibody titer in these participants 
negatively correlated with quantitative bacterial blood count at 
diagnosis and with cumulative symptom severity score following 
challenge, but not with temperature (Figures 2B,C; Table 1). We 
found no significant correlations when placebo TD was similarly 
analyzed (Table  1). Taken together, these observations suggest 
that higher bactericidal activity delayed the onset of infection and 
reduced disease severity in vaccinated participants.
The concentrations of various plasma cytokines associated 
with the acute phase of infection after S. Typhi challenge (26) 
were measured and analyzed to evaluate the impact of bacte-
ricidal activity on other events in disease pathogenesis. TNFα, 
IL6 and IL8 were negatively correlated with the D0 bactericidal 
titers in the vaccinated participants (Figures  2D–F; Table  1). 
However, CRP did not correlate with D0 titers (Table 1). There 
was no association between D0 titers and these cytokines for the 
placebo group (Table 1). These data corroborate an effect of bac-
tericidal antibody activity in reducing the inflammatory response 
during infection in live oral vaccine recipients. This was further 
supported by a vaccine subgroup analysis, which demonstrated 
stronger correlations in the M01ZH09 arm in whom the highest 
D0 bactericidal titers were observed (Table 1).
anti-lPs antibodies are the Key 
Mediators of Bactericidal activity
The concentrations of IgG and IgA to assorted S. Typhi antigens 
were measured to elucidate the antigen specificity of functional 
antibodies. Other than O9:LPS, flagellin, and Vi polysaccharide 
that are known key S. Typhi surface epitopes, we also tested 
responses to hemolysin E (HlyE), cytolethal distending protein 
subunit B (CdtB) and pilus control protein L (PilL). In antigen 
array experiments these antigens were previously found to be the 
dominant targets of circulating antibodies in patients with acute 
typhoid fever (27, 28). Negligible anti-Vi titers were observed in 
almost all tested samples (Figure S2A in Supplementary Material). 
In a mixed-effects model, we identified O9:LPS as being the most 
likely antigen targeted by bactericidal antibody with some activity 
also shown to flagellin (Table 2).
For confirmation, we depleted sera of antigen-specific anti-
bodies prior to assessing bactericidal activity. As shown in 
Figure 3, depletion of O9:LPS antibodies resulted in significant 
FigUre 1 | Kinetics of bactericidal antibody induction and decay. (a) Serum bactericidal antibody (SBA) titers in each study arm at D28 (pre-vaccination baseline), 
D0 (day of challenge), and D60 after challenge. (B) SBA titer kinetics after challenge in TD participants (filled diamonds) from each study arm. (c) SBA titers on D28, 
D0, and D60 after challenge in each study arm, shown for those with no typhoid diagnosis (nTD, empty circles). (D) SBA titers on the day of challenge, in those with 
typhoid diagnosis (TD) and nTD across all study arms. n.s., not significant, * p < 0.05; ** p < 0.01; *** p < 0.001. Asterisk within vertical lines indicates significance 
of pair-wise comparison between M01ZH09 and Ty21a vaccine arms for D0. Significance was determined by Wilcoxon signed rank test for paired value 
comparisons and by Mann–Whitney U-tests between groups.
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TaBle 1 | Statistical output following correlations of D0 bactericidal titers with clinical and immunological data in TD groups.
correlation statistics: [n] spearman rho (p-value)
Parameter all study arms M01Zh09 + Ty21a M01Zh09 Ty21a Placebo
Day of diagnosisa [29] 0.28 (0.145) [18] 0.58 (0.013) [11] 0.23 (0.502) [7] 0.73 (0.062) [11] −0.25 (0.466)
Bacterial countb [23] −0.20 (0.362) [14] −0.69 (0.006) [7] −0.67 (0.102) [7] −0.59 (0.168) [9] 0.10 (0.796)
Symptom severityc [30] −0.48 (0.007) [19] −0.52 (0.021) [11] −0.53 (0.095) [8] −0.73 (0.041) [11] −0.11 (0.746)
Max temperatured [30] −0.25 (0.178) [19] −0.26 (0.277) [11] −0.09 (0.792) [8] −0.74 (0.038) [11] −0.15 (0.649)
Max temperature increasee [30] −0.19 (0.314) [19] −0.18 (0.453) [11] −0.03 (0.925) [8] −0.47 (0.24) [11] −0.19 (0.569)
TNF-αf [20] −0.58 (0.007) [15] −0.60 (0.019) [7] −0.86 (0.014) [8] −0.48 (0.227) [5] −0.56 (0.322)
IL-6f [19] −0.20 (0.362) [14] −0.71 (0.005) [7] −0.84 (0.019) [7] −0.66 (0.111) [5] 0.21 (0.740)
IL-8f [20] −0.48 (0.007) [15] −0.69 (0.004) [7] −0.88 (0.019) [8] −0.74 (0.038) [5] −0.05 (0.935)
IL-1RAf [20] −0.30 (0.191) [15] −0.51 (0.051) [7] −0.73 (0.064) [8] −0.18 (0.668) [5] 0.05 (0.934)
IFN-γf [20] −0.17 (0.467) [15] −0.45 (0.091) [7] −0.76 (0.046) [8] −0.77 (0.025) [5] −0.41 (0.493)
CXCL10f [20] −0.12 (0.618) [15] −0.30 (0.271) [7] −0.47 (0.284) [8] −0.58 (0.133) [5] 0.41 (0.493)
Max CRPg [30] 0.06 (0.758) [19] −0.09 (0.714) [11] −0.28 (0.403) [8] −0.52 (0.188) [11] −0.01 (0.968)
Correlations with statistical significance are shown in bold.
aDay of diagnosis based on S. Typhi confirmed bacteremia or by ≥12 h of sustained fever of ≥38°C.
bCFU/mL per bacterial quantification of 10-mL blood sample collected on day of diagnosis.
cSymptom severity score, a cumulative score of solicited symptoms as defined in the Section “Materials and Methods.”
dMaximum temperature recorded during the challenge period.
eMaximum temperature increase during the challenge period.
fMaximum cytokine concentration in plasma samples collected within 48 h of diagnosis.
gMaximum C-reactive protein concentration recorded during the challenge period.
FigUre 2 | Bactericidal antibodies do not protect against typhoid infection but high bactericidal antibody activity reduces disease severity and cytokine response in 
vaccinated participants. (a–F) Correlation of disease parameters and plasma cytokine levels after diagnosis with SBA titers on D0 in participants from the Ty21a and 
M01ZH09 vaccine arms. Shown are day of diagnosis (a), bacterial load in blood on the day of diagnosis (B), symptom severity score (c), and maximum 
concentrations of cytokines TNFα, IL6, and IL8 [(D–F), respectively], in plasma samples collected within 48 h from diagnosis.
6
Juel et al. Bactericidal Antibodies and Typhoid Fever
Frontiers in Immunology | www.frontiersin.org January 2018 | Volume 8 | Article 1916
reduction in bactericidal titers from samples at baseline or at D28 
(both p = 0.009), independent of subset. In contrast, depleting 
antibodies specific to flagellin, or total IgA antibodies, did not 
affect activity (Figure 3).
Consistent with these bactericidal activity data, the numbers 
of IgM, IgA, or IgG antibody-secreting cells specific to O9:LPS 
present in circulation 7 days after vaccination were not associ-
ated with protection from typhoid fever (Figures S1B–D in 
Supplementary Material). Similarly, the D0 IgM, IgA, or IgG 
antibody titers against O9:LPS or flagellin were not associated 
with protection against development of disease (Figures S1E–G 
and S2B–D in Supplementary Material). Anti-O9:LPS antibody 
FigUre 3 | Bactericidal antibodies are specific to O9:LPS. SBA titer 
pre-vaccination (D28) and at D28 after challenge of samples undepleted 
(UD), or depleted of anti-H, anti-O9:LPS or total IgA antibodies. Diamonds 
indicate placebo, circles indicate Ty21a and squares indicate M01ZH09 
samples. Significance was determined by Wilcoxon signed rank tests.
TaBle 2 | Estimates and p-values from linear mixed-effects models of SBA data 
from all arms and time points to ELISA titers against specific antigens, taking 
into account random effects for grouping multiple time points from the same 
participants.
Parameters estimate (95% ci) p-Value
O lipopolysaccharide (O9:LPS) IgG 0.5957 (0.3, 0.9) 7.30E−05
O lipopolysaccharide (O9:LPS) IgA 0.9531 (0.7, 1.2) 1.60E−09
O lipopolysaccharide (O9:LPS) IgM 0.8876 (0.7, 1.1) 1.10E−13
Flagellin (H) IgG 0.3703 (−0.1,0.8) 0.123
Flagellin (H) IgA 0.5031 (0.1,1.0) 0.036
Flagellin (H) IgM 0.3078 (0.2, 0.4) 1.40E−06
Vi IgG 0.2538 (−0.1, 0.6) 0.109
HlyE IgG 0.6144 (0.1, 1.2) 0.037
HlyE IgA 0.3073 (−0.2, 0.8) 0.223
CdtB IgG 0.0978 (−0.4, 0.6) 0.718
CdtB IgA −0.0678 (−0.8, 0.6) 0.855
PilL IgG −0.0433 (−0.5, 0.4) 0.843
PilL IgA −0.1738 (−0.8, 0.5) 0.619
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titers showed a similar longitudinal profile to bactericidal activity 
(Figure 4). A notable exception was that anti-O9:LPS IgG signifi-
cantly increased in Ty21a TD participants following vaccination 
(p = 0.009 at D0) but not in response to challenge.
DiscUssiOn
This is the first direct investigation of the association between 
bactericidal activity and outcome of S. Typhi infection in 
humans, despite multiple in  vivo studies of murine challenge 
with Salmonella species (10, 29, 30) and typhoid vaccine clinical 
trials (6, 7). Alongside recent investigations of Shigella spp. and 
pseudomonas infection (31, 32) this study points to a moderat-
ing role for bactericidal antibodies common to multiple bacterial 
diseases.
We reported previously that vaccination with Ty21a or with 
M01ZH09-induced IgG antibodies against O9:LPS (14). Further 
analyses here show that in the Ty21a group this rise in anti-LPS 
IgG is limited to TD participants. Earlier studies found that vac-
cination with Ty21a induces anti-LPS IgG antibodies in serum 
(9) that opsonize ahead of phagocytic killing (12), but their role 
in complement-mediated bactericidal killing had not been inves-
tigated. It is noteworthy that levels of serum bactericidal activity 
did not significantly change after Ty21a vaccination, even in TD 
participants, perhaps reflecting the contribution of additional 
uncharacterized mutations in Ty21a (17). M01ZH09 induced 
significant rises in anti-O9:LPS IgG, IgA, and IgM titers and in 
bactericidal activity, consistent with previous immunogenicity 
studies (16, 33). We observed that these rises were highest in the 
group with TD after challenge.
Bactericidal activity is an established correlate of protection 
for Neisseria meningitidis and used in vaccine licensure (34, 35). 
Bactericidal antibodies have been associated with age-related 
decrease in incidence of invasive non-typhoidal Salmonella 
(NTS) disease in African children and an age-dependent increase 
in bactericidal activity titer has also been documented in areas of 
high typhoid incidence (36–38). However, in our study the deple-
tion of antibodies against O9:LPS abrogated bactericidal activity 
so it does not seem likely that either the presence, or bactericidal 
activity, of anti-LPS antibodies confers protection against inva-
sion by S. Typhi. The data presented here do not support the 
assumption that these functional antibodies have an important 
role in sterile immunity against S. Typhi in adults.
Consistent with an inability to prevent disease oral challenge 
with wild-type S. Typhi in naïve volunteers induced anti-LPS IgG, 
IgA, and IgM and bactericidal antibodies but the responses were 
limited to those who developed typhoid infection, as shown in 
previous studies of anti-LPS antibodies (15, 21). Similarly, Ty21a 
vaccine recipients who developed typhoid generated anti-LPS 
IgG and bactericidal antibodies in response to oral challenge. 
In contrast, in both Ty21a vaccinated and naïve individuals 
the exposure to LPS during invasive infection did not induce 
a bactericidal response among those who are challenged, and 
presumably have at least mucosal exposure to the pathogen, but 
do not succumb to infection.
The participants who received M01ZH09 vaccine also devel-
oped a rise in anti-LPS IgM antibodies following infection but 
no further rise in anti-LPS IgG, IgA, or bactericidal activity was 
observed. Repeat vaccination in a relatively short period of time 
can induce hyporesponsiveness to polysaccharide antigens (39, 40) 
and anergy to protein superantigens (41), both associated with 
saturation of the immune response and presumably a negative 
feedback control to avoid overstimulation of B  cells. However, 
bactericidal antibody titers in the M01ZH09 group were lower 
than those eventually attained in naive volunteers and Ty21a vac-
cine recipients. It seems more likely that the reduced bacterial load 
due to increased bactericidal activity from vaccination resulted in 
reduced exposure to LPS in this group, thus blunting any further 
FigUre 4 | Kinetics of O9:LPS antibody induction. Anti-O9:LPS IgM (a), IgA (B), and IgG (c) antibodies at baseline (D28), on the day of challenge (D0) and at D28, 
in those with typhoid diagnosis (TD, diamonds), and no typhoid diagnosis (nTD, empty circles) within each study arm. *p < 0.05, **p < 0.01, ***p < 0.001. 
Significance was determined by Wilcoxon signed rank tests for paired value comparisons.
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response. This is supported by significantly higher bactericidal 
titers in the M01ZH09 group than in the Ty21a volunteers at D0.
Variants of O9:LPS antigen are abundant in the Entero-
bacteriaceae, including gut commensals, which may explain the 
presence of baseline bactericidal activity and the strong boost 
upon challenge in the placebo and even the Ty21a subgroups. 
Consistent with our data, others have shown bactericidal activity 
resulting from anti-LPS antibodies in sera from mice immunized 
with S. Paratyphi A ΔguaBA ΔclpX or S. Typhi ΔguaBA ΔhtrA 
strains or invasive NTS isolates (10, 11, 29, 33). The serum bacte-
ricidal activity after vaccination or infection with S. Typhi is likely 
associated with anti-O9:LPS IgM or IgG complement-binding 
antibodies (42), as also observed with anti-O:LPS-mediated bac-
tericidal activity against NTS. Although secretory IgA activates 
the mannan-binding lectin pathway (43), depletion of IgA from 
our samples did not significantly affect bactericidal activity. In 
studies examining the role of bactericidal activity against NTS 
in African adults with or without HIV infection, bactericidal 
activity was not seen with anti-O:LPS IgA and the bactericidal 
properties of sera depended on the relative titers of anti-O:LPS 
isotypes so that high titers of IgA antibodies correlated with 
absence of bactericidal activity (37, 44). Other mechanisms may 
be at play for the absence of protection from typhoid challenge 
we observed.
Despite the absence of protection, among vaccinated partici-
pants the delay in onset of infection associated with higher bac-
tericidal antibody titer suggests that these antibodies may have 
an important role in reducing the bacterial load during infection, 
either at the point of invasion or during multiplication after the 
primary bacteremia. Additionally, the observed association with 
a reduction in disease manifestations and plasma cytokines sug-
gests a role for these antibodies in reducing inflammation and 
symptom severity. In previous CHIM studies of both typhoid 
and paratyphoid infection (15, 21), we have shown a relationship 
between challenge dose and duration of the incubation period as 
well as a challenge dose-dependent association with blood bacte-
rial load at diagnosis and anti-O:LPS titers. It is thus possible that 
the bactericidal activity of antibodies produced by vaccination 
reduced the bacterial load in the initial stages of infection and this 
in turn may have delayed disease onset or reduced other disease 
symptoms. This is consistent with a very recent investigation of 
shigellosis in a human challenge model and studies on patients 
with chronic Pseudomonas aeruginosa respiratory infections 
(31, 32). In these studies reduced SBA activity was associated 
with increased disease severity using parameters such as stool 
symptomatology and temperature (32) or lung forced expiratory 
volume (31). Bactericidal activity may also result in lower bacte-
rial burden in these cases.
Our analysis, which relies on gaining multiple samples from 
the same individuals, is limited by low statistical power. We 
were not able to determine the role of anti-Vi antibodies since 
the immune response to the capsular antigen was negligible. 
Nevertheless, the data imply that O9:LPS might not be the ideal 
antigen for new typhoid vaccines as neither the concentration 
of anti-O9:LPS antibody, frequency of anti-O9:LPS ASC nor 
bactericidal antibody titers at time of challenge correlated 
with protection in our model. Recent vaccine development for 
typhoid fever has focused on Vi-conjugate vaccines, but efforts to 
develop vaccines against invasive NTS strains (30, 45) and against 
S. Paratyphi have focused on O:LPS antigens (46). In contrast to 
S. Typhi, none of these pathogens are encapsulated with polysac-
charide. For S. Paratyphi B there is evidence from field trials that 
Ty21a provides cross-protection (47) and in our CHIM there 
is also evidence that anti-O2:LPS IgG titers may correlate with 
protection against S. Paratyphi A (21), thus examination of O 
polysaccharide-conjugate vaccines currently in development (46) 
in a CHIM is warranted. No such model for invasive NTS is avail-
able, and would raise some ethical concerns (13), to evaluate the 
role of bactericidal activity mediated by anti-O:LPS antibodies 
observed in vitro and in vivo (29, 37, 44). Future studies examining 
other antibody properties and cell-mediated mechanisms would 
enhance understanding of immunity to invasive Salmonellae.
We sought to identify the role of bactericidal antibodies in 
serum following challenge with S. Typhi in a human challenge 
model. We identified that anti-LPS antibodies mediate a bacte-
ricidal effect that delays onset of infection and reduces disease 
severity and inflammation. This directs future vaccine studies 
toward other antigens or mechanisms of protection against 
typhoid.
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FigUre s1 | Bactericidal antibodies do not protect against typhoid infection.  
(a) SBA titer on the day of challenge, in those with typhoid diagnosis (TD) and no 
typhoid diagnosis (nTD) within each study arm. Significance was determined by 
Mann–Whitney tests. (B–D) Numbers of cells secreting IgM (B), IgA (c), or IgG 
(D) antibodies against O9:LPS 7 days after vaccination, in TD and nTD groups 
across all study arms. Significance was determined by Mann–Whitney tests. 
(e–g) Antibody titers against O9:LPS IgM (e), O9:LPS IgA (F), and O9:LPS IgG 
(g) on the day of challenge (D0), in TD and nTD groups across all study arms. 
Significance was determined by Mann–Whitney tests.
FigUre s2 | Anti-Vi and anti-flagellin antibodies do not protect against typhoid 
infection. Antibody titers against Vi IgG (a), flagellin (H) IgM (B), H IgA (c), and H 
IgG (D) on the day of challenge (D0), in TD and nTD groups across all study 
arms. Significance was determined by Mann–Whitney tests.
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